Olatunji B. Alese, MD | Winship Cancer ...

Dr. Olatunji Alese

Claim this profile

Emory University Hospital/Winship Cancer Institute

Studies Pancreatic Cancer
Studies Colorectal Cancer
17 reported clinical trials
42 drugs studied

Area of expertise

1

Pancreatic Cancer

Olatunji Alese has run 6 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
PR positive
2

Colorectal Cancer

Olatunji Alese has run 4 trials for Colorectal Cancer. Some of their research focus areas include:

Stage IV
Stage III
RAS negative

Affiliated Hospitals

Image of trial facility.

Emory University Hospital/Winship Cancer Institute

Image of trial facility.

Emory University

Clinical Trials Olatunji Alese is currently running

Image of trial facility.

Targeted Therapy

for Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Recruiting

1 award

Phase 2

9 criteria

Image of trial facility.

Fruquintinib

for Colorectal Cancer

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.

Recruiting

3 awards

Phase 4

6 criteria

More about Olatunji Alese

Clinical Trial Related

8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Olatunji Alese has experience with

  • Nab-paclitaxel
  • Gemcitabine
  • Regorafenib
  • Irinotecan
  • Cetuximab
  • Dostarlimab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Olatunji Alese specialize in?

Is Olatunji Alese currently recruiting for clinical trials?

Are there any treatments that Olatunji Alese has studied deeply?

What is the best way to schedule an appointment with Olatunji Alese?

What is the office address of Olatunji Alese?

Is there any support for travel costs?